Boothbay Fund Management LLC Has $398,000 Holdings in Hologic, Inc. (NASDAQ:HOLX)

Boothbay Fund Management LLC trimmed its holdings in Hologic, Inc. (NASDAQ:HOLX) by 52.8% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 5,518 shares of the medical equipment provider’s stock after selling 6,167 shares during the period. Boothbay Fund Management LLC’s holdings in Hologic were worth $398,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in HOLX. General Partner Inc. acquired a new stake in shares of Hologic during the 4th quarter worth about $26,000. Venturi Wealth Management LLC raised its holdings in Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock valued at $31,000 after acquiring an additional 261 shares during the period. EverSource Wealth Advisors LLC lifted its position in Hologic by 79.8% during the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC grew its position in shares of Hologic by 36.9% in the fourth quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares during the last quarter. Finally, Smithfield Trust Co increased its stake in shares of Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 400 shares during the period. 94.73% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on HOLX. Morgan Stanley lowered their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Raymond James reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Citigroup lowered their target price on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a report on Tuesday, March 4th. Argus cut Hologic from a “buy” rating to a “hold” rating in a research note on Monday, March 3rd. Finally, Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 price objective on the stock. in a research note on Monday, February 3rd. Eleven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and an average price target of $84.62.

Hologic Stock Performance

Shares of HOLX stock opened at $57.28 on Friday. Hologic, Inc. has a one year low of $55.75 and a one year high of $84.67. The company has a market cap of $12.85 billion, a P/E ratio of 18.07, a P/E/G ratio of 2.14 and a beta of 0.82. The firm has a 50-day moving average of $60.50 and a 200-day moving average of $69.45. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. The firm had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. Hologic had a net margin of 18.42% and a return on equity of 19.72%. The company’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter last year, the firm earned $1.03 EPS. Equities research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.